You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国生物制药(01177.HK)上半年基本纯利增长20.5%至16.74亿元
格隆汇 08-28 19:13

格隆汇8月28日丨中国生物制药(01177.HK)发布中期业绩,截至2019年6月30日止6个月,公司实现收入125.27亿元人民币(下同),同比增长28.8%;归属于母公司持有者应占基本盈利16.74亿元,同比增长20.5%;归属于母公司持有者应占盈利14.44亿元,同比增长5.8%;基本每股收益11.47分;拟派中期股息每股4港仙。

报告期内,集团的销售形成多个增长亮点,收入构成更加均衡。借重磅1类原创新药福可维新上市契机,集团在全国多家医院开展上市后临床研究,并加强在肿瘤领域的专业推广,福可维显着的临床优势获更多医生和患者认识,销量持续强势增长,同时带动依固、依尼舒、首辅、赛维健等其他肿瘤相关产品快速增长。新上市用于成年多发性骨髓瘤产品安显(来那度胺胶囊)、治疗复发或难治性套细胞淋巴瘤产品千平(注射用硼替佐米)上市后销售表现优异,增长迅速。原有心血管用药托妥、依伦平,消化产品艾速平、呼吸产品天晴速乐增长稳健。镇痛产品得百安、抗感染产品天解及天礼亦进入放量增长期。

研发进入新一轮收获期:2019年上半年新获得生产批件11件(来那度胺胶囊、利奈唑胺葡萄糖注射液2个规格、安立生坦片、吉非替尼片、阿哌沙班片、钆塞酸二钠注射液、注射用醋酸卡泊芬净2个规格、替格瑞洛片、他达拉非片),其中多个具备大品种潜力。5个品种通过一致性评价,包括奥美沙坦酯片、福多司坦片、安立生坦片、吉非替尼片、阿哌沙班片;完成临床申报生产8件;新获得临床批准9件,其中4件为1类新药;新申报临床6件,均为1类新药。14件一致性评价申请获受理。新增发明专利授权33件,发明专利申请173件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account